Related references
Note: Only part of the references are listed.In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Cecilia G. Carvalhaes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014)
Robert K. Flamm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I
Yanqin Huang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile
Mikhail F. Gordeev et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
In Vitro, In Vivo, and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions
S. Flanagan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
Andrea C. Paula-Lima et al.
JOURNAL OF NEUROCHEMISTRY (2013)
Tedizolid (TR-701): a new oxazolidinone with enhanced potency
Zeina A. Kanafani et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative - An investigation using behavioral tests battery of depression
Radhakrishnan Mahesh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Zyvox® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008
Ronald N. Jones et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
Linezolid: a review of safety and tolerability
Donald C. Vinh et al.
JOURNAL OF INFECTION (2009)
Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825
Yukihiro Ikeda et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2008)
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections
Steven J. Brickner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Copper induced oxidation of serotonin: analysis of products and toxicity
Christopher E. Jones et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Ranbezolid, a novel oxazolidinone antibacterial:: In vivo characterisation of monoamine oxidase inhibitory potential in conscious rats
Krishna S. Naruganahalli et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Serotonin toxicity associated with the use of linezolid: A review of postmarketing data
KR Lawrence et al.
CLINICAL INFECTIOUS DISEASES (2006)
Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis
EE Nagiec et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
IDO and interferon-α-induced depressive symptoms:: a shift in hypothesis from tryptophan depletion to neurotoxicity
MC Wichers et al.
MOLECULAR PSYCHIATRY (2005)
The serotonin syndrome
EW Boyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A
F Reck et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
The pathophysiology of serotonin toxicity in animals and humans - Implications for diagnosis and treatment
GK Isbister et al.
CLINICAL NEUROPHARMACOLOGY (2005)
Clinical pharmacology of MAO inhibitors: Safety and future
M Yamada et al.
NEUROTOXICOLOGY (2004)
Acute delirium associated with combined diphenhydramine and linezolid use
RN Serio
ANNALS OF PHARMACOTHERAPY (2004)
Monoamine Oxidases: to Inhibit or Not to Inhibit
R. R. Ramsay et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2003)
Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using presser response to oral tyramine
EJ Antal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Share Paper
